Evidence map›Paper›PMID 39187577›Full record

ArticleScientific reports2024

Long COVID diagnostic with differentiation from chronic lyme disease using machine learning and cytokine hubs.

Bruce K Patterson, Jose Guevara-Coto, Javier Mora, Edgar B Francisco, Ram Yogendra, Rodrigo A Mora-Rodríguez, Christopher Beaty, Gwyneth Lemaster, Gary Kaplan DO, Amiram Katz and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. COVID-19 and Lung Cancer Interactions: A Literature Review.Medical sciences (Basel, Switzerland) · 2025
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bruce K PattersonIncellDx Inc, 30920 Huntwood Ave, San Carlos, Hayward, CA, 94544, USA. brucep@incelldx.com.
Jose Guevara-CotoIncellDx Inc, 30920 Huntwood Ave, San Carlos, Hayward, CA, 94544, USA.
Javier MoraLab of Tumor Chemosensitivity, Faculty of Microbiology, CIET/CICICA, Universidad de Costa Rica, San José, Costa Rica.
Edgar B FranciscoIncellDx Inc, 30920 Huntwood Ave, San Carlos, Hayward, CA, 94544, USA.
Ram YogendraLawrence General Hospital, Lawrence, MA, USA.
Rodrigo A Mora-RodríguezLab of Tumor Chemosensitivity, Faculty of Microbiology, CIET/CICICA, Universidad de Costa Rica, San José, Costa Rica.
Christopher BeatyIncellDx Inc, 30920 Huntwood Ave, San Carlos, Hayward, CA, 94544, USA.
Gwyneth LemasterIncellDx Inc, 30920 Huntwood Ave, San Carlos, Hayward, CA, 94544, USA.
Gary Kaplan DODepartment of Community and Family Medicine, Georgetown University School of Medicine, Washington, DC, USA.
Amiram KatzNeurology Specialist Affiliated With Norwalk Hospital, Orange, CT, USA.
Joseph A BellantiDepartments of Pediatrics and Microbiology-Immunology, and the International Center for Interdisciplinary Studies of Immunology, Georgetown University Medical Center, Washington, DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The absence of a long COVID (LC) or post-acute sequelae of COVID-19 (PASC) diagnostic has profound implications for research and potential therapeutics given the lack of specificity with symptom-based identification of LC and the overlap of symptoms with other chronic inflammatory conditions. Here, we report a machine-learning approach to LC/PASC diagnosis on 347 individuals using cytokine hubs that are also capable of differentiating LC from chronic lyme disease (CLD). We derived decision tree, random forest, and gradient-boosting machine (GBM) classifiers and compared their diagnostic capabilities on a dataset partitioned into training (178 individuals) and evaluation (45 individuals) sets. The GBM model generated 89% sensitivity and 96% specificity for LC with no evidence of overfitting. We tested the GBM on an additional random dataset (106 LC/PASC and 18 Lyme), resulting in high sensitivity (97%) and specificity (90%) for LC. We constructed a Lyme Index confirmatory algorithm to discriminate LC and CLD.

Indexed as

COVID-19CytokinesLyme DiseaseMachine LearningAdultAlgorithmsChronic DiseaseDiagnosis, DifferentialFemaleHumansMaleMiddle AgedPost-Lyme Disease SyndromeSARS-CoV-2Sensitivity and SpecificityCytokinesChronic lyme disease (CLD)COVID-19CytokinesLong COVIDMachine Learning/AIMyalgic encephalomyelitis-chronic fatigue syndrome (ME-CFS)PASC

Identifiers

PMID39187577
PMCPMC11347643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.